Company News: Allergan (AGN) quarterly results beat analysts’ expectations

Market news

5 November 2019

Company News: Allergan (AGN) quarterly results beat analysts’ expectations

Allergan (AGN) reported Q3 FY 2019 earnings of $4.25 per share (versus $4.25 in Q3 FY 2018), beating analysts’ consensus estimate of $4.20.

The company’s quarterly revenues amounted to $4.026 bln (+2.9% y/y), beating analysts’ consensus estimate of $3.881 bln.

The company also issued guidance for FY 2019, projecting EPS of >$16.55 versus analysts’ consensus estimate of $16.74 and revenues of $15.6-15.8 bln compared to its prior guidance of $15.4-15.6 bln and analysts’ consensus estimate of $15.58.

AGN rose to $179.74 (+0.53%) in pre-market trading.

Canada's merchandise trade deficit likely to narrow to $600m in September – TDS

EU's chief Brexit negotiator Barnier: Brexit is not only about divorce, so many consequences are underestimated

Market Focus

Material posted here is solely for information purposes and reliance on this may lead to losses. Past performances are not a reliable indicator of future results. Please read our full disclaimer

Open Demo Account & Personal Page

Personal area

support@teletradepartners.com

Risk Warning: Trading in the financial markets (including trading on margin) provides a wide range of opportunities and enables investors ready to take risks to make high profits, but it carries a potentially high level of risk of loss. Therefore, prior to trading you should take into careful consideration whether such operations are suitable for you in terms of your level of knowledge and financial situation.